Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04124042 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of XT-150 in Osteoarthritis of the Knee
A Phase 2 study, sponsored by Xalud Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 289
- Enrollment target
NCT04124042 is a Phase 2 study that has completed, run by Xalud Therapeutics. The registered enrollment target is 289 participants.
The verdict
NCT04124042, a Phase 2 study, has completed, sponsored by Xalud Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 289 participants
- Enrollment target
Study Summary
This is a Phase 2 safety and efficacy study of XT-150 in adult participants experiencing moderate to severe pain due to osteoarthritis of the knee.
Interventions
- DRUG Placebo
- BIOLOGICAL XT-150
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 289 participants |
| Start Date | 2020-02-14 |
| Est. Completion | 2022-04-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04124042
The ClinicalTrials.gov registry entry for NCT04124042 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 289 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xalud Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04124042 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04124042 about?
NCT04124042 is a clinical study titled "Efficacy and Safety of XT-150 in Osteoarthritis of the Knee". This is a Phase 2 safety and efficacy study of XT-150 in adult participants experiencing moderate to severe pain due to osteoarthritis of the knee.
What is the current status of trial NCT04124042?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 289 participants. The study started on 2020-02-14. Estimated completion is 2022-04-26.
What interventions are being tested in trial NCT04124042?
The interventions under investigation include: Placebo (DRUG), XT-150 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04124042?
This trial is sponsored by Xalud Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.